Cogent Biosciences
COGT
69 hedge funds and large institutions have $370M invested in Cogent Biosciences in 2020 Q4 according to their latest regulatory filings, with 43 funds opening new positions, 17 increasing their positions, 9 reducing their positions, and 8 closing their positions.
438% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 8
307% more capital invested
Capital invested by funds: $91M → $370M (+$279M)
97% more funds holding
Funds holding: 35 → 69 (+34)
89.27% more ownership
Funds ownership: 23.86% → 113.14% (+89%)
89% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 9
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
United Kingdom
|
+$18.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$16.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$13.7M |
| 4 |
PA
Perceptive Advisors
New York
|
+$13.2M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$12.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$9.14M |
| 2 |
Millennium Management
New York
|
-$2.82M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$959K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$757K |
COGT Hedge Fund Activity: Q4 2020 in Review
69 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Cogent Biosciences (COGT) for Q4 2020, worth a combined $370M — up 307% from $91M a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new COGT positions and 8 closed out — a net gain of 35 holders — while 17 added to existing stakes and 9 trimmed.
The largest buyer was Janus Henderson Group, adding an estimated $18.1M. The largest seller was Samsara BioCapital, cutting an estimated $9.14M.
- 69 institutional investors held Cogent Biosciences (COGT) as of Q4 2020, up from 35 in Q3 2020.
- Funds reported $370M of Cogent Biosciences stock for Q4 2020, up 307% quarter-over-quarter.
- 43 funds opened new Cogent Biosciences positions in Q4 2020 and 8 closed out, a net change of +35 holders.
- The largest Cogent Biosciences buyer in Q4 2020 was Janus Henderson Group, an estimated $18.1M added.
- The largest Cogent Biosciences seller in Q4 2020 was Samsara BioCapital, an estimated $9.14M sold.
Based on aggregated 13F filings for Q4 2020.